Transpact Ent Peer Comparison

BSE: 542765

₹85.75

₹-4.50 (-4.99%)

As on 24-Aug-2026IST

Market cap

₹3 Cr

Revenue (TTM)

₹0 Cr

P/E Ratio

38.1

P/B Ratio

7.3

Div. Yield

0 %

Edit

	Transpact Ent	Poly Medicure	Q-Line Biotech	Saakshi Medtech	Nureca
Market cap (₹ Cr)	3	17,553	1,281	582	316
Revenue (₹ Cr)	0	1,997	314	92	153
Net Profit (₹ Cr)	0.01	307.01	24.51	4.71	4.34
Net Margin (%)	--	14.56	7.60	5.06	2.70
RoE (%)	2.01	10.63	13.94	4.92	2.29
Price to Earnings	38.12	55.71	22.98	47.39	72.90
Price-To-Book	7.34	5.52	6.05	4.17	1.72

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Transpact Ent	Poly Medicure	Q-Line Biotech	Saakshi Medtech	Nureca
Operating Revenue	0.08	1,669.83	313.78	92.43	109.66
Total Income	0.08	1,758.96	322.58	93.00	122.37
Total Expenditure	0.04	1,214.12	239.29	82.12	117.47
EBITDA	0.04	455.71	74.49	10.31	-7.81
Depreciation	0.04	83.18	7.32	3.89	2.34
EBIT	0.01	372.53	67.17	6.42	-10.15
Interest	0.00	14.32	14.81	0.41	1.21
Other Income	--	89.13	8.80	0.57	12.71
Exceptional Items	--	--	-16.97	--	--
Profit before Tax	0.00	452.52	44.19	6.59	1.34
Provision for Tax	0.00	113.96	19.68	1.88	0.50
Profit after Tax	0.01	338.56	24.51	4.71	0.85

Liabilities (₹ Cr)

	Transpact Ent	Poly Medicure	Q-Line Biotech	Saakshi Medtech	Nureca
Shareholder's Funds	0.45	2,765.66	189.95	98.04	194.29
Minority Interest	--	--	--	--	--
Non-Current Liabilities	0.02	56.40	85.42	14.44	-0.18
Current Liabilities	0.23	457.71	179.14	18.62	12.40
Total Liabilities	0.70	3,279.77	455.49	131.33	209.98

Assets (₹ Cr)

	Transpact Ent	Poly Medicure	Q-Line Biotech	Saakshi Medtech	Nureca
Non-Current Assets	0.13	1,269.89	189.87	76.67	16.55
Current Assets	0.57	2,009.87	264.64	54.44	189.95
Total Assets	0.70	3,279.77	455.49	131.33	209.98
Total Debt*	0.10	177.65	166.29	17.82	2.37
Net Current Assets	0.34	1,552.17	85.50	35.81	177.55
Contingent Liabilities	--	77.12	--	5.29	0.02

Cashflow (₹ Cr)

	Transpact Ent	Poly Medicure	Q-Line Biotech	Saakshi Medtech	Nureca
Cash From Operating Activities	-0.40	233.05	-1.28	3.02	-19.08
Cash Flow from Investing Activities	--	-1,187.18	-59.13	-14.74	8.44
Cash from Financing Activities	--	950.51	53.34	-0.60	-0.17
Net Cash Inflow / Outflow	-0.40	-3.63	-7.07	-12.32	-10.81

Ratios

Profitability Ratios

	Transpact Ent	Poly Medicure	Q-Line Biotech	Saakshi Medtech	Nureca
ROCE (%)	0.95	20.37	19.19	6.16	1.31
ROE (%)	2.01	16.01	13.94	4.92	0.44
ROA (%)	1.33	12.99	6.18	3.60	0.42
EBIT Margin (%)	51.15	32.63	26.54	11.77	4.46
Net Margin (%)	10.91	19.25	7.60	5.06	0.69
Cash Profit Margin (%)	56.00	25.15	10.15	7.98	2.61

Growth Ratios

	Transpact Ent	Poly Medicure	Q-Line Biotech	Saakshi Medtech	Nureca
Revenue Growth (%)	--	21.37	54.08	-24.14	19.29
EBIT Growth (%)	173.01	30.11	103.82	-46.94	1,494.46
Net Profit Growth (%)	109.90	31.09	13.27	-58.34	147.16
EPS Growth (%)	109.90	24.16	-18.34	-58.34	147.16
Book Value Growth (%)	2.03	88.41	17.38	5.05	0.61

Valuation Ratios

	Transpact Ent	Poly Medicure	Q-Line Biotech	Saakshi Medtech	Nureca
Price / Earnings	833.55	67.10	0.00	48.10	248.64
Price / Book Value	16.62	8.22	0.00	2.31	1.08
Dividend Yield (%)	0.00	0.16	--	0.00	0.00
EV/EBITDA	179.98	41.75	1.45	22.15	17.43
Market Cap (₹ Cr)	7.50	22,718.23	0.00	226.53	210.35

Solvency Ratios

	Transpact Ent	Poly Medicure	Q-Line Biotech	Saakshi Medtech	Nureca
Debt to Equity	0.22	0.06	0.88	0.18	0.01
Short term debt to equity ratio	0.22	0.06	0.29	0.00	0.00
Current Ratio	2.49	4.39	1.48	2.92	15.32
Quick Ratio	2.44	3.77	0.97	1.83	12.10
Interest Coverage	6.25	32.59	3.98	17.26	2.11

Operating Efficiency Ratios

	Transpact Ent	Poly Medicure	Q-Line Biotech	Saakshi Medtech	Nureca
Debtors to sales (%)	117.82	20.94	26.32	23.68	3.03
Asset Turnover	0.12	0.64	0.79	0.82	0.60
Receivable days	218.34	67.43	63.42	66.41	7.39
Inventory Days	55.30	55.13	113.68	71.27	105.87
Payable days	--	74.14	143.90	54.28	31.48
Cash Conversion Cycle	--	48.42	33.20	83.40	81.78

Annual
Quarterly